Enanta Pharmaceuticals, Inc. (ENTA)
NASDAQ: ENTA · Real-Time Price · USD
12.52
-0.18 (-1.42%)
Sep 17, 2026, 4:00 PM EDT - Market closed
Enanta Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is October - September.
Millions USD. Fiscal year is Oct - Sep.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 |
Operating Revenue | 65.26 | 65.32 | 67.64 | 79.2 | 86.16 | 97.07 |
| 65.26 | 65.32 | 67.64 | 79.2 | 86.16 | 97.07 | |
Revenue Growth | 0.70% | -3.42% | -14.61% | -8.07% | -11.24% | -20.74% |
Gross Profit | 65.26 | 65.32 | 67.64 | 79.2 | 86.16 | 97.07 |
Selling, General & Admin | 37.75 | 43.93 | 57.85 | 52.89 | 45.48 | 32.54 |
Research & Development | 86.24 | 106.74 | 131.48 | 163.52 | 164.52 | 174.11 |
Operating Expenses | 123.99 | 150.67 | 189.33 | 216.41 | 210 | 206.65 |
Operating Income | -58.73 | -85.35 | -121.69 | -137.21 | -123.84 | -109.57 |
Interest Expense | -12.92 | -7.68 | -10.94 | -5.15 | - | - |
Interest & Investment Income | 7.85 | 9.95 | 13.63 | 8.5 | 2.74 | 2.02 |
Other Non Operating Income (Expenses) | 0.04 | 0.04 | 0.07 | - | 0.08 | -0.03 |
EBT Excluding Unusual Items | -63.76 | -83.05 | -118.93 | -133.85 | -121.02 | -107.58 |
Gain (Loss) on Sale of Investments | 0.63 | -0.5 | 1.14 | 2.86 | -1.17 | - |
Pretax Income | -63.13 | -83.55 | -117.79 | -131 | -122.19 | -107.58 |
Income Tax Expense | 0.1 | -1.66 | -1.74 | 2.82 | -0.43 | -28.58 |
Net Income | -63.23 | -81.89 | -116.05 | -133.82 | -121.76 | -79 |
Net Income to Common | -63.23 | -81.89 | -116.05 | -133.82 | -121.76 | -79 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 27 | 21 | 21 | 21 | 21 | 20 |
Shares Outstanding (Diluted) | 27 | 21 | 21 | 21 | 21 | 20 |
Shares Change | 27.12% | 0.85% | 0.90% | 1.78% | 2.14% | 1.16% |
EPS (Basic) | -2.34 | -3.84 | -5.48 | -6.38 | -5.91 | -3.92 |
EPS (Diluted) | -2.34 | -3.84 | -5.48 | -6.38 | -5.91 | -3.92 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 |
Free Cash Flow | -36.94 | -32.17 | -96.71 | -112.21 | -86.91 | -70.75 |
Free Cash Flow Per Share | -1.36 | -1.51 | -4.57 | -5.35 | -4.22 | -3.51 |
Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
Operating Margin | -89.99% | -130.66% | -179.92% | -173.23% | -143.74% | -112.88% |
Profit Margin | -96.89% | -125.36% | -171.58% | -168.95% | -141.31% | -81.38% |
Free Cash Flow Margin | -56.61% | -49.24% | -142.99% | -141.67% | -100.87% | -72.88% |
EBITDA | -53.82 | -80.76 | -119.36 | -134.84 | -120.87 | -106.24 |
EBITDA Margin | -82.47% | -123.63% | -176.47% | -170.24% | -140.29% | -109.44% |
D&A For EBITDA | 4.91 | 4.59 | 2.34 | 2.37 | 2.97 | 3.33 |
EBIT | -58.73 | -85.35 | -121.69 | -137.21 | -123.84 | -109.57 |
EBIT Margin | -89.99% | -130.66% | -179.92% | -173.23% | -143.74% | -112.88% |
Revenue as Reported | 65.26 | 65.32 | 67.64 | 79.2 | 86.16 | 97.07 |